Antibodies
23 December 2013
Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis23 December 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors20 December 2013
Roche’s new subcutaneous formulation of RoACTEMRA gains CHMP positive opinion in Europe for moderate to severe rheumatoid arthritis20 December 2013
FibroGen Announces Patient Enrollment in New Phase 2 Clinical Study of FG-3019 for the Treatment of Idiopathic Pulmonary Fibrosis19 December 2013
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol19 December 2013
Sandoz begins Phase III clinical trial for biosimilar adalimumab18 December 2013
Roche and Genentech Acquire Unlimited Access to Open Monoclonal Technology’s OmniRat18 December 2013
GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukemia (CLL)18 December 2013
Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients17 December 2013
Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol17 December 2013
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe10 December 2013
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody10 December 2013
ImmunoGen, Inc. Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat Patient Population10 December 2013
MorphoSys Announces Additional Clinical Trial of MOR208 Phase 2 Study in CLL will Evaluat10 December 2013
FDA Advisory Committee Recommends Approval of Takeda’s Investigational Biologic Vedolizumab10 December 2013
Seattle Genetics Highlights Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 20139 December 2013
Dyax Presents Investigational DX-2930 and Biomarker Assay Data at the 2013 American Society of Hematology Annual Meeting9 December 2013
ImmunoGen, Inc. Announces Favorable Initial Safety and Response Findings for CD38-Targeting Anticancer Compound, SAR6509848 December 2013
NKT Therapeutics Reports First Clinical Results with anti-iNKT Antibody in Patients with Sickle Cell Disease8 December 2013
Siltuximab Pivotal Trial Data Show Efficacy for Treatment of Patients with Multicentric Castleman’s DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports